Kathryn J. Collier - May 20, 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
May 20, 2024
Transactions value $
$0
Form type
4
Date filed
5/21/2024, 04:22 PM
Previous filing
May 17, 2024
Next filing
Jul 29, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +60K $0.00 60K May 20, 2024 Common Stock 60K $2.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service.